3-methyl-1-pentyl methanesulfonate | 72132-79-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 3-methyl-1-pentyl methanesulfonate
• 英文别名: 3-methylpentyl methanesulfonate
• CAS: 72132-79-7
• 化学式: C₇H₁₆O₃S
• 分子量: 180.268
• InChiKey: XXGHTSHVCKEDPN-UHFFFAOYSA-N

物化性质

• 沸点：
  270.6±9.0 °C(Predicted)
• 密度：
  1.048±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-methyl-1-pentyl methanesulfonate 在 sodium iodide 作用下， 以 丙酮 为溶剂， 生成 1-碘-3-甲基-戊烷
  参考文献：
  名称：

  [EN] REAGENTS AND METHODS FOR ALIPHATIC CARBON—HYDROGEN BOND FUNCTIONALIZATION
  [FR] RÉACTIFS ET PROCÉDÉS DE FONCTIONNALISATION DE LIAISON CARBONE-HYDROGÈNE ALIPHATIQUE

  摘要：

  The subject matter contained herein relates generally to methods and compounds that facilitate aliphatic carbon-hydrogen bond functionalization by group transfer via a nitrogen-centered radical in the presence of a trap, and the functionalized compounds prepared therefrom. The subject matter described herein provides a platform and the ability to efficiently and selectively introduce a range of valuable functionality on diverse hydrocarbon substrates ranging from methane to polyolefins with >3500 carbon atoms. As described herein, the reagents employed can form reactive N-centered radicals, the kinetics of which do not compete with companion radical traps. This technology finds usefulness in enhancing capabilities in late-stage diversification, while the molecules and materials now made accessible can provide solutions to important challenges in medicinal chemistry and materials science.

  公开号：

  WO2022241129A1
• 作为产物：
  描述：

  3-甲基-1-戊醇 、 甲基磺酰氯 在 三乙胺 作用下， 以 乙醚 为溶剂， 生成 3-methyl-1-pentyl methanesulfonate
  参考文献：
  名称：

  [EN] REAGENTS AND METHODS FOR ALIPHATIC CARBON—HYDROGEN BOND FUNCTIONALIZATION
  [FR] RÉACTIFS ET PROCÉDÉS DE FONCTIONNALISATION DE LIAISON CARBONE-HYDROGÈNE ALIPHATIQUE

  摘要：

  The subject matter contained herein relates generally to methods and compounds that facilitate aliphatic carbon-hydrogen bond functionalization by group transfer via a nitrogen-centered radical in the presence of a trap, and the functionalized compounds prepared therefrom. The subject matter described herein provides a platform and the ability to efficiently and selectively introduce a range of valuable functionality on diverse hydrocarbon substrates ranging from methane to polyolefins with >3500 carbon atoms. As described herein, the reagents employed can form reactive N-centered radicals, the kinetics of which do not compete with companion radical traps. This technology finds usefulness in enhancing capabilities in late-stage diversification, while the molecules and materials now made accessible can provide solutions to important challenges in medicinal chemistry and materials science.

  公开号：

  WO2022241129A1

文献信息

• Substituted heterocycle fused gamma-carbolines
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：US06713471B1

  公开（公告）日：2004-03-30

  The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

  本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R1、R5、R6a、R6b、R7、R8、R9、X、b、k、m和n以及虚线在本文中描述。本发明还涉及包含这些新化合物作为活性成分的药物制剂以及利用这些新化合物及其制剂治疗某些疾病。本发明的化合物是5-羟色胺激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症、焦虑症、抑郁症、精神病、精神分裂症、睡眠障碍、性功能障碍、偏头痛、头痛相关疾病、社交恐惧症以及胃肠道疾病，如胃肠道运动功能障碍。
• Kinetics and mechanism of elimination of primary alkyl methanesulfonates in the gas phase: correlation of alkyl substituents
  作者：Gabriel Chuchani、Sarah Pekerar、Rosa M. Dominguez、Alexandra Rotinov、Ignacio Martin

  DOI：10.1021/j100338a042

  日期：1989.1
• HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE
  申请人：Ventana Medical Systems, Inc.

  公开号：EP2078197B1

  公开（公告）日：2016-03-23
• USRE039679E1
  申请人：——

  公开号：——

  公开（公告）日：——
• SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1192165A2

  公开（公告）日：2002-04-03